Novo Nordisk Issues Recall of Wegovy Injection Due to Contamination
Novo Nordisk recalled Wegovy (semaglutide) injections on December 19, 2025, after discovering hair in prefilled syringes. The contamination poses a serious hazard to consumers. The recall affects all units distributed nationwide.
Product Details
The recall involves Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, packaged as 4 Single-Dose Prefilled Pens. The affected lot numbers are RZFHD52 and RZFHW93, with an expiration date of October 31, 2026. The product was distributed throughout the United States.
The Hazard
The recalled product contains particulate matter, specifically hair, in the prefilled syringe. This contamination can lead to serious health risks if injected.
Reported Incidents
No specific injuries or incidents have been reported related to this recall. The presence of hair in a medication delivery system raises significant health concerns.
What to Do
Consumers and healthcare providers should stop using Wegovy immediately. Contact Novo Nordisk Inc. or your healthcare provider for further guidance.
Contact Information
For assistance, consumers can reach Novo Nordisk Inc. at their Plainsboro, NJ office or visit the FDA's website for more information.